|
| Press Releases |
|
 |
|
| Tuesday, June 27, 2017 |
|
|
Eisai Temporarily Withdraws New Drug Application for Anticancer Agent Halaven in China |
| Eisai Co., Ltd. announced today that, in alignment with Chinese regulations, it has temporarily withdrawn its new drug application for anticancer agent eribulin mesylate (Brand name: Halaven) in China in order to submit additional documentation. more info >> |
|
| Friday, June 23, 2017 |
|
|
Eisai Submits Application for Additional Indication of Anticancer Agent Lenvima for Hepatocellular Carcinoma in Japan |
| Eisai Co., Ltd. announced today that it has submitted an application for an additional indication of its in-house discovered and developed anticancer agent Lenvima (generic name: lenvatinib mesylate) for the treatment of hepatocellular carcinoma (HCC) in Japan, the first in the world. more info >> |
|
|
Cardiovascular Outcomes Trial of Anti-Obesity Agent Lorcaserin to Continue Based on Recommendation of Independent Data Monitoring Committee After Completion of Interim Safety Analysis |
| Eisai Co., Ltd. has announced that it has received a recommendation from an independent Data Monitoring Committee to continue the ongoing Cardiovascular Outcomes Trial of lorcaserin hydrochloride after the completion of a pre-specified interim safety analysis, evaluating the incidence of Major Adverse Cardiovascular Events (MACE), defined as cardiovascular death, myocardial infarction or stroke. more info >> |
|
| Thursday, June 8, 2017 |
|
|
Launch of Pain Treatment Lyrica OD Tablet Formulation in Japan |
| Pfizer Japan Inc. and Eisai Co., Ltd. have announced that Lyrica OD Tablets 25mg, 75mg, 150mg (OD tablet: orally disintegrating tablet), a new formulation following pain treatment Lyrica Capsules (pregabalin). more info >> |
|
| Monday, June 5, 2017 |
|
|
Eisai to Present Results of Phase III Trial of Lenvima (Lenvatinib) as First-Line Treatment for Unresectable Hepatocellular Carcinoma in Oral Session at 53rd ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that the results of a Phase III trial (Study 304) of its in-house discovered and developed anticancer agent lenvatinib mesylate against the comparator sorafenib as first-line treatment for unresectable hepatocellular carcinoma, will be orally presented during the 53rd Annual Meeting of ASCO. more info >> |
|
|
Eisai to Present Results of Phase Ib/II Study of Anticancer Agent Lenvima (Lenvatinib) in Combination With Anti-PD-1 Antibody Pembrolizumab |
| Eisai Co., Ltd. announced the first results for metastatic endometrial carcinoma obtained from a Phase Ib/II study (Study 111) of its in-house developed multi-kinase inhibitor lenvatinib mesylate in combination with the MSD anti-PD-1 antibody pembrolizumab (brand name: KEYTRUDA), during a presentation at the 53rd Annual Meeting of ASCO. more info >> |
|
| Thursday, June 1, 2017 |
|
|
Eisai Commits Funding to the 2nd Phase of Global Health Innovative Technology Fund Activities |
| Eisai Co., Ltd. has announced that it will grant a total of 500 million yen to the Global Health Innovative Technology Fund (GHIT Fund) to fund the second phase of its activities, which will take place in the five-year period from FY 2018 to FY 2022. more info >> |
|
| Wednesday, May 31, 2017 |
|
|
Eisai Enters Into a New Joint Research Agreement With the Broad Institute to Develop an Antimalarial Medicine |
| Eisai Co., Ltd. announced today that it has entered into a new joint research agreement with the Broad Institute, a collaborative research institute which includes researchers from the Massachusetts Institute of Technology and Harvard University to develop a new antimalarial medicine based on antimalarial drug targets the team identified last year. more info >> |
|
| Thursday, May 18, 2017 |
|
|
Eisai to Present Abstracts on Oncology Products and Pipeline at 53rd ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results for its in-house discovered lenvatinib mesylate and eribulin mesylate, as well as H3B-8800 will be presented during the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO). more info >> |
|
| Wednesday, April 19, 2017 |
|
|
Eisai Announces Results and Continued Support of Initiatives for Elimination of Lymphatic Filariasis |
| Eisai Co., Ltd. has announced the results of its initiatives for the elimination of lymphatic filariasis (LF), and its continued support of this cause in the future. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Ordify Employs Blockpass to Open Investment to Everyone
May 3, 2024 13:38: JST
|
|
|
Singapore's top general insurer debuts trading on Asia's leading digital exchange, AltaX
May 3, 2024 10:30 HKT/SGT
|
|
|
Nephros Schedules First Quarter 2024 Financial Results Conference Call
May 3, 2024 08:31 HKT/SGT
|
|
|
Nass Valley Gateway Ltd Announces It Will File Its 2023 EOY Audited Financials by June 28th, 2024, Within the Extension Granted by the BCSC
May 3, 2024 08:26 HKT/SGT
|
|
|
UPDATE: Kaplan Fox Files Class Action to Recover Losses for Investors Who Were Short The Barclays Bank PLC iPath Series B S&P 500 VIX Short-Term Futures ETN (CBOE: VXX) ("VXX")
May 3, 2024 08:05 HKT/SGT
|
|
|
长江电力公布2023年年度业绩 营收利润双增长
May 2, 2024 23:00 HKT/SGT
|
|
|
長江電力公佈2023年年度業績 營收利潤雙增長
May 2, 2024 22:54 HKT/SGT
|
|
|
SMEStreet Celebrates 10 Years of Serving Indian MSMEs
May 2, 2024 22:20 HKT/SGT
|
|
|
Hong Kong International Licensing Show creates cross-industry business opportunities
May 2, 2024 21:18 HKT/SGT
|
|
|
CITIC Telecom CPC Garners Multiple Ecosystem Partners Awards Reinforces Collaborative Capabilities, Drives Breakthrough Innovation & Shares Sustainable Development Results
May 2, 2024 21:17 HKT/SGT
|
|
|
INNIO Group's 2023 Sustainability Report: Progress in Implementing Corporate Sustainability Goals
May 2, 2024 21:16 HKT/SGT
|
|
|
FTLife Pre-Announces Name Change to Chow Tai Fook Life Insurance Company Limited
May 2, 2024 21:15 HKT/SGT
|
|
|
New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
May 2, 2024 22:13 JST
|
|
|
Loop Industries and Ester Industries Ltd. Announce Joint Venture Agreement to Build an Infinite Loop(TM) Manufacturing Facility in India
May 2, 2024 21:12 HKT/SGT
|
|
|
SDAI Limited: Positive Outcomes Since New Board took over in June 2023
May 2, 2024 21:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
